The MFDS announced on the 29th that it has revised and distributed the "Guidelines for applying rapid screening of medicines" so that even early cancer patients can participate in clinical trials, considering the difficulty of recruiting large-scale phase 3 clinical trials for terminal cancer patients.

However, even in the early stages of the disease, cancer, which can confirm clinical effects and safety at the end of the disease, is allowed, and domestic and foreign screening cases will be comprehensively reviewed and strictly applied after sufficient advice from experts.

The MFDS permits patients who do not have a cure or who need a new treatment due to failure to comply with the effect or